Trials / Completed
CompletedNCT00729209
A Study of ARRY-371797 in Patients With Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1 study, involving a 29-day treatment period, designed to evaluate the pharmacokinetics and the effectiveness of investigational study drug ARRY-371797 in treating rheumatoid arthritis in patients receiving stable doses of methotrexate, and to further evaluate the drug's safety. Approximately 30 patients from the US will be enrolled in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARRY-371797, p38 inhibitor; oral | multiple dose, single schedule |
| DRUG | Placebo; oral | matching placebo |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2008-08-07
- Last updated
- 2020-09-21
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00729209. Inclusion in this directory is not an endorsement.